Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurological Sciences
Erschienen in: Neurological Sciences 8/2020

13.04.2020 | Review Article

Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer’s disease

verfasst von: Rakesh Kumar Singh

Erschienen in: Neurological Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Alzheimer’s disease is a complex multifaceted neurodegenerative disorder. It is characterized by the deposition of extracellular amyloid senile plaques and intracellular neurofibrillary tangles leading to progressive dementia and death in aged adult population. Recent emerging research has highlighted a potential pharmacological role of 5-lipoxyenase-cysteinyl leukotriene pathway in molecular pathogenesis of Alzheimer’s disease.

Objective

Although cysteinyl leukotrienes and their receptors have a major clinical role in chronic respiratory inflammation, their roles in chronic neuroinflammation in Alzheimer’s disease need a detailed and careful exploration.

Results and conclusion

This review article highlights a novel role of cysteinyl leukotrienes and their receptors in pathophysiology of Alzheimer’s disease in order to understand the underlying molecular mechanism. In addition, it summarizes the recent advances in various pre-clinical and clinical strategies used to modulate this pathway for therapeutic targeting of Alzheimer’s disease.
Literatur
1.
Cummings J, Lee G, Rittera A, Zhong K (2014) Alzheimer’s disease drug development pipeline: 2018. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4:195–214
2.
Kozlov S, Afonin A, Evsyukov I, Bondarenko A (2017) Alzheimer’s disease: as it was in the beginning. Rev Neurosci 28:825–843PubMedCrossRef
3.
Picanço, LCdS, Ozela PF, Brito MdFdB, Pinheiro AA, Padilha EC, Braga FS, Silva CHTdPd, Santos CBRd, Rosad JMC and Hage-Melim LIdS (2018) Alzheimer’s disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr Med Chem 25:3141–3159
4.
Sala Frigerio C, De Strooper B (2016) Alzheimer’s disease mechanisms and emerging roads to novel therapeutics. Annu Rev Neurosci 39:57–59PubMedCrossRef
5.
Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C (2017) Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci 24:46–54PubMedPubMedCentralCrossRef
6.
Kalra J, Khan A (2015) Reducing Aβ load and tau phosphorylation: emerging perspective for treating Alzheimer’s disease. Eur J Pharmacol 764:571–581PubMedCrossRef
7.
Wang F, Liu H, Shen X, Ao H, Moore N, Gao L, Chen L, Hu H, Ma H, Yang Z (2015) The combined treatment of amyloid-β1-42-stimulated bone marrow–derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer’s disease in APPswe/PSENldE9 mice. Neurobiol Aging 36:111–122PubMedCrossRef
8.
Hsieh HL, Yang CM (2013) Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioMed Research International 2013
9.
Mufson EJ, Ikonomovic MD, Counts SE, Perez SE, Malek-Ahmadi M, Scheff SW, Ginsberg SD (2016) Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behavioral Brain Research 311:54–69CrossRef
10.
Wang J, Gu BJ, Masters CL, Wang Y-J (2017) A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 13:612–623PubMedCrossRef
11.
12.
Kumar A, Prakash A, Pahwa D, Mishra J (2012) Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacol Biochem Behav 103:43–52PubMedCrossRef
13.
Vickers JC, Mitew S, Woodhouse A, Fernandez-Martos CM, Kirkcaldie MT, Canty AJ, McCormack GH, King AE (2016) Defining the earliest pathological changes of Alzheimer’s disease. Curr Alzheimer Res 13:281–287PubMedPubMedCentralCrossRef
14.
Zhang XY, Chen L, Yang Y, Xu DM, Zhang SR, Li CT, Zheng W, Yu SY, Wei EQ, Zhang LH (2014) Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1. Brain Res 1572:59–71PubMedCrossRef
15.
Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D (2012) 5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of AD. Ann Neurol 72:442–454PubMedPubMedCentralCrossRef
16.
17.
Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease. FASEB J 22:1169–1178PubMedCrossRef
18.
Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L (2017) Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases. Mediat Inflamm 2017:1–15CrossRef
19.
Rahman SO, Singh RK, Hussain S, Akhtar M, Najmi AK (2019) A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer’s disease. Eur J Pharmacol 842:208–220PubMedCrossRef
20.
Singh R, Gupta S, Dastidar S, Ray A (2010) Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 85:336–349PubMedCrossRef
21.
Singh RK, Tandon R, Dastidar SG, Ray A (2013) A review on leukotrienes and their receptors with reference to asthma. J Asthma 50:922–931PubMedCrossRef
22.
Al-Amran FG, Hadi NR, Hashim AM (2013) Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur J Cardiothorac Surg 43:421–427PubMedCrossRef
23.
Czapski GA, Czubowicz K, Strosznajder JB, Strosznajder RP (2016) The lipoxygenases: their regulation and implication in Alzheimer’s disease. Neurochem Res 41:243–257PubMedCrossRef
24.
Ghosh A, Chen F, Thakur A, Hong H (2016) Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neuroscience & Therapeutics 22:943–951CrossRef
25.
Klegeris A, McGeer PL (2002) Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 23:787–794PubMedCrossRef
26.
Tang SS, Hong H, Chen L, Mei ZL, Ji MJ, Xiang GQ, Li N, Ji H (2014) Involvement of cysteinyl leukotriene receptor 1 in Aβ1-42-induced neurotoxicity in vitro and in vivo. Neurobiol Aging 35:590–599PubMedCrossRef
27.
Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, Samuelsson B, Rådmark O, Sautebin L, Werz O (2008) ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proceedings of National Academy of Sciences, USA 105:19881–19886CrossRef
28.
Fang SH, Wei EQ, Zhou Y, Wang ML, Zhang WP, Yu GL, Chu LS, Chen Z (2006) Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 140:969–979PubMedCrossRef
29.
Fang SH, Zhou Y, Chu LS, Zhang WP, Wang ML, Yu GL, Peng F, Wei EQ (2007) Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci Lett 412:78–83PubMedCrossRef
30.
Yu SY, Zhang XY, Wang XR, Xu DM, Chen L, Zhang LH, Fang SH, Lu YB, Zhang WP, Wei EQ (2014) Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro. Acta Pharm Sin 35:33–40CrossRef
31.
Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX, Brunden KR (2015) Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors. Sci Rep 5:18286PubMedPubMedCentralCrossRef
32.
Huber C, Marschallinger J, Tempfer H, Furtner T, Couillard-Despres S, Bauer HC, Rivera FJ, Aigner L (2011) Inhibition of leukotriene receptors boosts neural progenitor proliferation. Cell Physiol Biochem 28:793–804PubMedCrossRef
33.
Kuo CH, Yang SN, Kuo HF, Lee MS, Huang MY, Huang SK, Lin YC, Hsieh CC, Hung CH (2016) Cysteinyl leukotriene receptor antagonist epigenetically modulates cytokine expression and maturation of human myeloid dendritic cells. Pulmonary Pharmacology and Therapeutics 39:28–37PubMedCrossRef
34.
Marschallinger J, Schaffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichne P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer H-C, Singewald N, Blumcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbracchio MP and Aigner L (2015) Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug Nature Communications 6
35.
Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, Villa G, Verderio C, Grumelli C and Guerrini U (2008) The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PloS One 3
36.
Austen K, Maekawa A, Kanaoka Y, Boyce J (2009) The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 124:406–414PubMedPubMedCentralCrossRef
37.
Cai Z, Hussain MD, Yan LJ (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 124:307–321PubMedCrossRef
38.
39.
Chai Q, He WQ, Zhou M, Lu H, Fu ZF (2014) Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J Virol 88:4698–4710PubMedPubMedCentralCrossRef
40.
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRef
41.
Kaunzner UW, Miller MM, Gottfried-Blackmore A, Gal-Toth J, Felger JC, McEwen BS, Bulloch K (2012) Accumulation of resident and peripheral dendritic cells in the aging CNS. Neurobiol Aging 33:681–693PubMedCrossRef
42.
Kuca K, Soukup O, Maresova P, Korabecny J, Nepovimova E, Klimova B, Honegr J, Ramalhob TC, França TCC (2016) Current approaches against Alzheimer’s disease in clinical trials. J Braz Chem Soc 27:641–649
43.
Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67:195–203PubMedCrossRef
44.
Manev H, Chen H, Dzitoyeva S, Manev R (2011) Cyclooxygenases and 5-lipoxygenase in Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 35:315–319CrossRef
45.
46.
Nunan J, Small DH (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 483:6–10PubMedCrossRef
47.
Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer’s disease. Journal of Histochemistry & Cytochemistry 56:1065–1073CrossRef
48.
Cui J, Wang X, Li X, Wang X, Zhang C, Li W, Zhang Y, Gu H, Xie X, Nan F, Zhao J and Pei G (2015) Targeting the γ-/β-secretase interaction reduces β-amyloid generation and ameliorates Alzheimer’s disease-related pathogenesis Cell Discovery 18
49.
Giannopoulos PF, Chu J, Sperow M, Li JG, Yu WH, Kirby LG, Abood M, Praticò D (2015) Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry 78:693–701PubMedPubMedCentralCrossRef
50.
Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W (2012) Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol 15:77–90PubMedCrossRef
51.
Chen F, Ghosh A, Wu F, Tang S, Hu M, Sun H, Kong L, Hong H (2017) Preventive effect of genetic knockdown and pharmacological blockade of CysLT1R on lipopolysaccharide (LPS)-induced memory deficit and neurotoxicity in vivo. Brain Behav Immun 60:255–269PubMedCrossRef
52.
Chen L, Yang Y, Li CT, Zhang SR, Zheng W, Wei EQ, Zhang LH (2015) CysLT2 receptor mediates lipopolysaccharide-induced microglial inflammation and consequent neurotoxicity in vitro. Brain Res 1624:433–445PubMedCrossRef
53.
Hawkes CA, Shaw JE, Brown M, Sampson AP, McLaurin J, Carare RO (2014) MK886 reduces cerebral amyloid angiopathy severity in TgCRND8 mice. Neurodegener Dis 13:17–23PubMed
54.
Joshi YB, Praticò D (2015) The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype. Front Cell Neurosci 8:1–8CrossRef
55.
Kalra J, Kumar P, Majeed AB, Prakash A (2016) Modulation of LOX and COX pathways via inhibition of amyloidogenesis contributes to mitoprotection against beta-amyloid oligomer-induced toxicity in an animal model of Alzheimer’s disease in rats. Pharmacol Biochem Behav 146-147:1–12PubMedCrossRef
56.
McGeer PL, McGeer EG (2015) Targeting microglia for the treatment of Alzheimer’s disease. Expert Opin Ther Targets 19:497–506PubMedCrossRef
57.
Engelhardt B, Carare RO, Bechmann I, Flügel A, Laman JD, Weller RO (2016) Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol 132:317–338PubMedPubMedCentralCrossRef
58.
Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 94:1077–1098PubMedCrossRef
59.
Pekny M, Wilhelmsson U, Pekna M (2014) The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 565:30–38PubMedCrossRef
60.
Tiernan CT, Mufson EJ, Kanaan NM, Counts SE (2018) Tau oligomer pathology in nucleus basalis neurons during the progression of Alzheimer disease. J Neuropathol Exp Neurol 77:246–259PubMedPubMedCentralCrossRef
61.
Ghosh AK, Brindisi M, Tang J (2012) Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem 120:71–83PubMedCrossRef
62.
Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC (2014) Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin 30:2021–2032PubMedCrossRef
63.
Ilarraza R, Wu Y, Adamko DJ (2012) Montelukast inhibits leukotriene stimulation of human dendritic cells in vitro. Int Arch Allergy Immunol 159:422–427PubMedCrossRef
64.
Lai J, Hu M, Wang H, Hu M, Long Y, Miao MX, Li JC, Wang XB, Kong LY, Hong H (2014) Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 79:707–714PubMedCrossRef
65.
Lai J, Mei ZL, Wang H, Hu M, Long Y, Miao MX, Li N, Hong H (2014) Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-kappaB signaling. Neurochem Int 75:26–31PubMedCrossRef
66.
67.
Shi SS, Yang WZ, Tu XK, Wang CH, Chen CM, Chen Y (2013) 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia. Inflammation 36:1209–1217PubMedCrossRef
68.
Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba S, Siggins G, Piomelli D, 1996. . J. Neurochem. 66 and 147–152. (1996) Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J Neurochem 66:147–152
69.
Gezen-Ak D, Dursun E, Hanağası H, Bilgiç B, Lohman E, Araz ÖS, Atasoy İL, Alaylıoğlu M, Önal B, Gürvit H (2013) BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. J Alzheimers Dis 37:185–195PubMedCrossRef
70.
Shi QJ, Wang H, Liu ZX, Fang SH, Song XM, Lu YB, Zhang WP, Sa XY, Ying HZ, Wei EQ (2015) HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience 291:53–69PubMedCrossRef
71.
Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, Chen L, Fang SH, Lu YB, Zhang WP, Wei EQ (2013) HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther 346:328–341PubMedCrossRef
72.
Bouvier DS, Murai KK (2015) Synergistic actions of microglia and astrocytes in the progression of Alzheimer’s disease. J Alzheimers Dis 45:1001–1014PubMedCrossRef
73.
Huang XJ, Zhang WP, Li CT, Shi WZ, Fang SH, Lu YB, Chen Z, Wei EQ (2008) Activation of CysLT receptors induces astrocyte proliferation and death after oxygen–glucose deprivation. Glia 56:27–37PubMedCrossRef
74.
Huang XQ, Zhang XY, Wang XR, Yu SY, Fang SH, Lu YB, Zhang WP and Wei EQ (2012) Transforming growth factor beta1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor. Journal of Neuroinflammation 9
75.
Falkowska A, Gutowska I, Goschorska M, Nowacki P, Chlubek D, Baranowska-Bosiacka I (2015) Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. Int J Mol Sci 16:25959–25981PubMedPubMedCentralCrossRef
76.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487PubMedPubMedCentralCrossRef
77.
Thal DR (2012) The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol 236:1–5PubMedCrossRef
78.
Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VMY, Pratico D (2004) Modulation of nuclear factor-κB activity by indomethacin influences Aβ levels but not Aβ precursor protein metabolism in a model of Alzheimer’s disease. Am J Pathol 165:2197–2206PubMedPubMedCentralCrossRef
79.
Wang XY, Tang SS, Hu M, Long Y, Li YQ, Liao MX, Ji H, Hong H (2013) Leukotriene D4 induces amyloid-beta generation via CysLT(1)R-mediated NF-kappaB pathways in primary neurons. Neurochem Int 62:340–347PubMedCrossRef
80.
Chamorro A, Dirnagl U, Urra X, Planas AM (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15:869–881PubMedCrossRef
81.
82.
Singh P, Sharma B (2016) Reversal in cognition impairments, cholinergic dysfunction, and cerebral oxidative stress through the modulation of ryanodine receptors (RyRs) and Cysteinyl leukotriene-1 (CysLT1) receptors. Curr Neurovasc Res 13:10–21PubMedCrossRef
83.
Honma T, Hatta K, Hitomi Y, Kambayashi Y, Hibino Y, Konoshita T, Nakamura H (2013) Increased systemic inflammatory interleukin-1ß and interleukin-6 during agitation as predictors of Alzheimer’s disease. Int J Geriatr Psychiatry 28 (3):233–241
84.
Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB, Lee VM (2011) The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies. Pharmacol Res 63:341–351PubMedCrossRef
85.
Ong W-Y, Farooqui T, Kokotos G, Farooqui AA (2015) Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci 6:814–831PubMedCrossRef
86.
Di Meco A, Lauretti E, Vagnozzi AN, Praticò D (2014) Zileuton restores memory impairments and reverses amyloid and tau pathology in aged mice. Neurobiol Aging 35:2458–2464PubMedPubMedCentralCrossRef
Metadaten
Titel
Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer’s disease
verfasst von
Rakesh Kumar Singh
Publikationsdatum
13.04.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 8/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04369-7

Weitere Artikel der Ausgabe 8/2020

Neurological Sciences 8/2020 Zur Ausgabe

COVID-19

Containing COVID-19 in a specialised neurology centre: the risks of presymptomatic transmission

COVID-19

Early neurological manifestations of hospitalized COVID-19 patients

Original Article

Platelet dysfunction and coagulation assessment in patients of tuberculous meningitis

Original Article

Clinical exome sequencing in neuromuscular diseases: an experience from Turkey

Brief Communication

Treating dissociative post-traumatic stress disorder presenting as a functional movement disorder with transcranial magnetic stimulation targeting the cingulate gyrus

Original Article

Listening to the neurological teams for multiple sclerosis: the SMART project

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise